SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Eikon Therapeutics EIK1001 Combination Shows 72.4% Response Rate

Eikon Therapeutics said its EIK1001 combination showed a 72.4% response rate in a squamous lung cancer trial.

EIKN

Related stories